A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, J.H. | - |
dc.contributor.author | Chang, I.H. | - |
dc.date.accessioned | 2024-01-18T09:00:22Z | - |
dc.date.available | 2024-01-18T09:00:22Z | - |
dc.date.issued | 2022-07 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.issn | 2466-054X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71093 | - |
dc.description.abstract | In the past, there was no second-line chemotherapeutic agent suitable for use when urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several new treatment options, such as immune checkpoint inhibitors or targeted therapy have shifted the treatment paradigm regarding second-line therapeutic modalities. A novel class of therapeutic agents includes an antibody-drug conjugate (ADC). ADCs consist of three characteristics: a monoclonal antibody, linker, and payload. The specificity of the monoclonal antibody facilitates the delivery of a linked cytotoxic drug directly into the target tumor cell. Although various ADCs have been developed and approved for use in treating several solid tumors, almost all ADCs for the treatment of UC are still in the testing phase. Here, we review the key points about ADCs and summarize the novel ADCs that are approved or are involved in ongoing studies in UC. © The Korean Urological Association. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Urological Association | - |
dc.title | A novel strategy for treatment of bladder cancer: Antibody-drug conjugates | - |
dc.type | Article | - |
dc.identifier.doi | 10.4111/icu.20220061 | - |
dc.identifier.bibliographicCitation | Investigative and Clinical Urology, v.63, no.4, pp 373 - 384 | - |
dc.identifier.kciid | ART002857256 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000827269100002 | - |
dc.identifier.scopusid | 2-s2.0-85133872238 | - |
dc.citation.endPage | 384 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 373 | - |
dc.citation.title | Investigative and Clinical Urology | - |
dc.citation.volume | 63 | - |
dc.type.docType | Review | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Antibody-drug conjugate | - |
dc.subject.keywordAuthor | Bladder cancer | - |
dc.subject.keywordAuthor | Immunoconjugates | - |
dc.subject.keywordAuthor | Immunotherapy | - |
dc.subject.keywordAuthor | Urinary bladder neoplasms | - |
dc.subject.keywordPlus | METASTATIC UROTHELIAL CARCINOMA | - |
dc.subject.keywordPlus | TISSUE FACTOR | - |
dc.subject.keywordPlus | SOLID TUMORS | - |
dc.subject.keywordPlus | SACITUZUMAB GOVITECAN | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.